Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VPM1002 to reduce severe respiratory infections in elderly during SARS-CoV-2 pandemic
2020-001675-33Phase 3Completed
- Sponsor
- Vakzine Projekt Management
- Start
- Apr 2020
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Airways Infection and coronavirus disease 2019 (COVID-19) comparing VPM1002 with Placebo (2 arms). Primary endpoint: Number of days with severe respiratory disease at hospital and/or at home. Started Apr 2020; status: completed.
02
Drugs
VPM1002
03
Conditions
Airways Infectioncoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001675-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001675-33.